Resmed – Buying Opportunity

Out of the three healthcare buy recommendations, (CSL, SHL and RMD),   made in the blog post back on 13th of September, CSL has increased 10% and SHL 10%+, however, RMD has been slower to recover. With the recent price action in RMD, we’re now more confident that a basing pattern, (or reversal), is beginning to take shape. Therefore, today’s post acts as a reminder that a buy opportunity in RMD remains, with an upside target of $9.00+

Resmed (RMD.ASX)

You’re not a member!  Trial today

rmd

 

 

 

Ready to elevate your investing?

Join Investor Signals today and start your journey to better, more disciplined returns.